Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Non Receptor Tyrosine Protein Kinase TYK2 Market by Type (ARRY-624, BMS-986165, Cerdulatinib, NDI-031232, Others), By Application (Follicular Lymphoma, Hypersensitivity, Lupus Nephritis, Marginal Zone B-cell Lymphoma, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Non Receptor Tyrosine Protein Kinase TYK2 Market by Type (ARRY-624, BMS-986165, Cerdulatinib, NDI-031232, Others), By Application (Follicular Lymphoma, Hypersensitivity, Lupus Nephritis, Marginal Zone B-cell Lymphoma, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 309955 4200 Pharma & Healthcare 377 192 Pages 4.8 (47)
                                          

Industry Growth Insights published a new data on “Non Receptor Tyrosine Protein Kinase TYK2 Market”. The research report is titled “Non Receptor Tyrosine Protein Kinase TYK2 Market research by Types (ARRY-624, BMS-986165, Cerdulatinib, NDI-031232, Others), By Applications (Follicular Lymphoma, Hypersensitivity, Lupus Nephritis, Marginal Zone B-cell Lymphoma, Others), By Players/Companies Array BioPharma Inc, Bristol-Myers Squibb Company, Nimbus Therapeutics LLC, Pfizer Inc, Portola Pharmaceuticals Inc, Sareum Holdings Plc, Takeda Pharmaceutical Company Ltd, Theravance Biopharma Inc, Array BioPharma Inc”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Non Receptor Tyrosine Protein Kinase TYK2 Market Research Report

By Type

ARRY-624, BMS-986165, Cerdulatinib, NDI-031232, Others

By Application

Follicular Lymphoma, Hypersensitivity, Lupus Nephritis, Marginal Zone B-cell Lymphoma, Others

By Companies

Array BioPharma Inc, Bristol-Myers Squibb Company, Nimbus Therapeutics LLC, Pfizer Inc, Portola Pharmaceuticals Inc, Sareum Holdings Plc, Takeda Pharmaceutical Company Ltd, Theravance Biopharma Inc, Array BioPharma Inc

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

192

Number of Tables & Figures

135

Customization Available

Yes, the report can be customized as per your need.


Global Non Receptor Tyrosine Protein Kinase TYK2 Industry Outlook


Global Non Receptor Tyrosine Protein Kinase TYK2 Market Report Segments:

The global Non Receptor Tyrosine Protein Kinase TYK2 market is segmented on the basis of:

Types

ARRY-624, BMS-986165, Cerdulatinib, NDI-031232, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Follicular Lymphoma, Hypersensitivity, Lupus Nephritis, Marginal Zone B-cell Lymphoma, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Array BioPharma Inc
  2. Bristol-Myers Squibb Company
  3. Nimbus Therapeutics LLC
  4. Pfizer Inc
  5. Portola Pharmaceuticals Inc
  6. Sareum Holdings Plc
  7. Takeda Pharmaceutical Company Ltd
  8. Theravance Biopharma Inc
  9. Array BioPharma Inc

Global Non Receptor Tyrosine Protein Kinase TYK2 Market Overview


Highlights of The Non Receptor Tyrosine Protein Kinase TYK2 Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. ARRY-624
    2. BMS-986165
    3. Cerdulatinib
    4. NDI-031232
    5. Others
  1. By Application:

    1. Follicular Lymphoma
    2. Hypersensitivity
    3. Lupus Nephritis
    4. Marginal Zone B-cell Lymphoma
    5. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Non Receptor Tyrosine Protein Kinase TYK2 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Non Receptor Tyrosine Protein Kinase TYK2 Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


TYK2 is a non-receptor tyrosine protein kinase. TYK2 is responsible for the phosphorylation of proteins in response to extracellular signals. TYK2 has been shown to play a role in cell growth, survival, and motility.

Some of the major players in the non receptor tyrosine protein kinase tyk2 market are Array BioPharma Inc, Bristol-Myers Squibb Company, Nimbus Therapeutics LLC, Pfizer Inc, Portola Pharmaceuticals Inc, Sareum Holdings Plc, Takeda Pharmaceutical Company Ltd, Theravance Biopharma Inc, Array BioPharma Inc.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Non Receptor Tyrosine Protein Kinase TYK2 Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Non Receptor Tyrosine Protein Kinase TYK2 Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Non Receptor Tyrosine Protein Kinase TYK2 Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Non Receptor Tyrosine Protein Kinase TYK2 Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Non Receptor Tyrosine Protein Kinase TYK2 Market Size & Forecast, 2020-2028       4.5.1 Non Receptor Tyrosine Protein Kinase TYK2 Market Size and Y-o-Y Growth       4.5.2 Non Receptor Tyrosine Protein Kinase TYK2 Market Absolute $ Opportunity

Chapter 5 Global  Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2  Market Size Forecast by Type
      5.2.1 ARRY-624
      5.2.2 BMS-986165
      5.2.3 Cerdulatinib
      5.2.4 NDI-031232
      5.2.5 Others
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global  Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2  Market Size Forecast by Applications
      6.2.1 Follicular Lymphoma
      6.2.2 Hypersensitivity
      6.2.3 Lupus Nephritis
      6.2.4 Marginal Zone B-cell Lymphoma
      6.2.5 Others
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Non Receptor Tyrosine Protein Kinase TYK2 Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Non Receptor Tyrosine Protein Kinase TYK2 Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America  Analysis and Forecast
   9.1 Introduction
   9.2 North America  Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America  Market Size Forecast by Type
      9.6.1 ARRY-624
      9.6.2 BMS-986165
      9.6.3 Cerdulatinib
      9.6.4 NDI-031232
      9.6.5 Others
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America  Market Size Forecast by Applications
      9.10.1 Follicular Lymphoma
      9.10.2 Hypersensitivity
      9.10.3 Lupus Nephritis
      9.10.4 Marginal Zone B-cell Lymphoma
      9.10.5 Others
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe  Analysis and Forecast
   10.1 Introduction
   10.2 Europe  Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe  Market Size Forecast by Type
      10.6.1 ARRY-624
      10.6.2 BMS-986165
      10.6.3 Cerdulatinib
      10.6.4 NDI-031232
      10.6.5 Others
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe  Market Size Forecast by Applications
      10.10.1 Follicular Lymphoma
      10.10.2 Hypersensitivity
      10.10.3 Lupus Nephritis
      10.10.4 Marginal Zone B-cell Lymphoma
      10.10.5 Others
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific  Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific  Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific  Market Size Forecast by Type
      11.6.1 ARRY-624
      11.6.2 BMS-986165
      11.6.3 Cerdulatinib
      11.6.4 NDI-031232
      11.6.5 Others
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific  Market Size Forecast by Applications
      11.10.1 Follicular Lymphoma
      11.10.2 Hypersensitivity
      11.10.3 Lupus Nephritis
      11.10.4 Marginal Zone B-cell Lymphoma
      11.10.5 Others
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America  Analysis and Forecast
   12.1 Introduction
   12.2 Latin America  Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America  Market Size Forecast by Type
      12.6.1 ARRY-624
      12.6.2 BMS-986165
      12.6.3 Cerdulatinib
      12.6.4 NDI-031232
      12.6.5 Others
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America  Market Size Forecast by Applications
      12.10.1 Follicular Lymphoma
      12.10.2 Hypersensitivity
      12.10.3 Lupus Nephritis
      12.10.4 Marginal Zone B-cell Lymphoma
      12.10.5 Others
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA)  Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA)  Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA)  Market Size Forecast by Type
      13.6.1 ARRY-624
      13.6.2 BMS-986165
      13.6.3 Cerdulatinib
      13.6.4 NDI-031232
      13.6.5 Others
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA)  Market Size Forecast by Applications
      13.10.1 Follicular Lymphoma
      13.10.2 Hypersensitivity
      13.10.3 Lupus Nephritis
      13.10.4 Marginal Zone B-cell Lymphoma
      13.10.5 Others
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Non Receptor Tyrosine Protein Kinase TYK2 Market: Competitive Dashboard
   14.2 Global Non Receptor Tyrosine Protein Kinase TYK2 Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Array BioPharma Inc
      14.3.2 Bristol-Myers Squibb Company
      14.3.3 Nimbus Therapeutics LLC
      14.3.4 Pfizer Inc
      14.3.5 Portola Pharmaceuticals Inc
      14.3.6 Sareum Holdings Plc
      14.3.7 Takeda Pharmaceutical Company Ltd
      14.3.8 Theravance Biopharma Inc
      14.3.9 Array BioPharma Inc

Our Trusted Clients

Contact Us